Larimar Therapeutics (NASDAQ:LRMR) Director Frank Thomas Acquires 8,000 Shares of Stock

Key Points

• Larimar Therapeutics director Frank Thomas bought 8,000 shares at $2.73 each, spending $21,840 and increasing his direct stake by 114.29% to 15,000 shares.
• LRMR shares slipped 1.1% to $2.70; the stock has traded between $1.91 and $6.42 over the past year. Institutional investors own about 91.92% of the company.
• Analysts’ consensus rating is Buy, with an average price target of $10.33, though ratings range from Strong Buy to Sell.

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) Director Frank Thomas purchased 8,000 shares of the company's stock in a transaction that occurred on Wednesday, November 11th. The shares were acquired at an average price of $2.73 per share, for a total transaction of $21,840.00. Following the completion of the acquisition, the director directly owned 15,000 shares of the company's stock, valued at $40,950. This trade represents a 114.29% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Larimar Therapeutics Stock Down 1.1%

LRMR stock traded down $0.03 during midday trading on Thursday, hitting $2.70. The company's stock had a trading volume of 1,190,176 shares, compared to its average volume of 2,378,292. The stock's 50-day moving average price is $2.97 and its 200 day moving average price is $3.77. Larimar Therapeutics, Inc. has a 1 year low of $1.91 and a 1 year high of $6.42. The stock has a market cap of $280.48 million, a price-to-earnings ratio of -1.38 and a beta of 0.73.

Institutional Trading of Larimar Therapeutics

Large investors have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Larimar Therapeutics in the 2nd quarter valued at about $17,318,000. AIGH Capital Management LLC bought a new stake in shares of Larimar Therapeutics during the third quarter valued at about $5,911,000. Dimensional Fund Advisors LP lifted its holdings in shares of Larimar Therapeutics by 143.8% in the first quarter. Dimensional Fund Advisors LP now owns 798,462 shares of the company's stock worth $3,592,000 after buying an additional 470,968 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Larimar Therapeutics by 148.9% in the first quarter. Renaissance Technologies LLC now owns 739,942 shares of the company's stock worth $3,330,000 after buying an additional 442,676 shares in the last quarter. Finally, SummitTX Capital L.P. bought a new position in shares of Larimar Therapeutics in the first quarter valued at approximately $1,709,000. 91.92% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on LRMR. Weiss Ratings restated a "sell (d-)" rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Wedbush reaffirmed an "outperform" rating on shares of Larimar Therapeutics in a research report on Tuesday. Finally, Leerink Partners began coverage on shares of Larimar Therapeutics in a research note on Monday, September 14th. They issued an "outperform" rating and a $13.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $10.33.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich's ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar's approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.